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Abstract: The platinum (Pt)-group elements (PGEs) represent a new kind of environmental 
pollutant and a new hazard for human health. Since their introduction as vehicle-exhaust catalysts, 
their emissions into the environment have grown considerably compared with their low natural 
concentration in the earth crust. PGE emissions from vehicle catalysts can be also in the form of 
nanometer-sized particles (Pt nanoparticles [PtNPs]). These elements, both in their metallic form 
or as ions solubilized in biological media, are now recognized as potent allergens and sensitizers. 
Human skin is always exposed to toxic particles; therefore, in the present study we addressed the 
question of whether polyvinylpyrrolidone-coated PtNPs may have any negative effects on skin 
cells, including predominantly epidermal keratinocytes. In this study, PtNPs of two sizes were 
used: 5.8 nm and 57 nm, in concentrations of 6.25, 12.5, and 25 µg/mL. Both types of NPs were 
protected with polyvinylpyrrolidone. Primary keratinocytes were treated for 24 and 48 hours, 
then cytotoxicity, genotoxicity, morphology, metabolic activity, and changes in the activation of 
signaling pathways were investigated in PtNP-treated cells. We found that PtNPs trigger toxic 
effects on primary keratinocytes, decreasing cell metabolism, but these changes have no effects 
on cell viability or migration. Moreover, smaller NPs exhibited more deleterious effect on DNA 
stability than the big ones. Analyzing activation of caspases, we found changes in activity of 
caspase 9 and caspase 3/7 triggered mainly by smaller NPs. Changes were not so significant in 
the case of larger nanoparticles. Importantly, we found that PtNPs have antibacterial properties, 
as is the case with silver NPs (AgNPs). In comparison to our previous study regarding the effects 
of AgNPs on cell biology, we found that PtNPs do not exhibit such deleterious effects on primary 
keratinocytes as AgNPs and that they also can be used as potential antibacterial agents, especially 
in the treatment of Escherichia coli, representing a group of Gram-negative species.
Keywords: platinum nanoparticles, keratinocytes, migration, signaling pathways, DNA dam-
age, toxicity
Introduction
The platinum (Pt)-group elements (PGEs) represent a new kind of environmental pol-
lutant and a new hazard for human health. Since their introduction as vehicle-exhaust 
catalysts, their emissions into the environment have grown considerably compared with 
their low natural concentration in the earth crust.1 PGE contamination initially occurs in 
airborne particulate matter, roadside dust, soil, sludge, and water, and afterwards results 
in bioaccumulation in living organisms through different pathways.2 Traditionally, these 
elements are considered to be nontoxic for human health, but the massive use of Pt, 
palladium (Pd), and rhodium (Rh) as nanoparticles (NPs) and automotive catalytic 
converters, causing their release into the environment, has determined a new risk 
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of nanometer-sized particles.3 These elements, both in their 
metallic form or as ions solubilized in biological media, are 
now recognized as potent allergens and sensitizers.1,4 They 
have been also associated with asthma, dermatitis, and other 
serious health problems in humans, resulting from chronic 
exposure at low concentration levels.5
The effects of PtNPs on different types of cells are not 
fully clarified. It is generally accepted that PtNPs are not 
as toxic as silver NPs and exhibit remarkable antioxidant 
activities, reducing reactive oxygen species (ROS) produc-
tion.6–8 Because of this strong antioxidative capacity, PtNPs 
have been effectively used in the cosmetic sector in antiag-
ing formulations. Human skin is constantly exposed to solar 
ultraviolet photons. Therefore, the formation of ROS, as 
mediators of photooxidative stress, occurs on a daily basis, 
especially in countries with enhanced sun exposure. The sun’s 
ultraviolet ray-driven ROS production in skin cells results in 
changes in skin structural integrity, signal transduction, gene 
expression, and even tumorigenic initiation and progres-
sion.9,10 The use of antioxidative agents in skin cosmetics 
could provide positive effects on skin condition. Thus, there 
is a potential probability that PtNPs will be commonly used 
in cosmetics in the future.
As there have not been any data concerning the impact of 
PtNPs on primary keratinocytes so far, in the present study 
we addressed the question of whether polyvinylpyrrolidone 




In this study, PtNPs of two sizes were used: 5.8 nm and 
57 nm. Both types of NP were coated with PVP and dissolved 





, adapting the method described for palladium NPs by 
Choo et al.11 Transmission electron microscopy (TEM) mea-
surements revealed that PtNPs were as small as 5.8 ± 0.9 nm 
(number of measured NPs: 100). Total Pt concentration was 
measured by inductively coupled plasma atomic emission 
spectroscopy: the determined concentration of PtNPs in the 
initial NP suspension was 2.0 g/L. A limulus amebocyte lysate 
endotoxin assay was used to confirm that the PtNP solution was 
free of bacterial endotoxins and endotoxin-like substances. The 
bigger NPs were ordered from Particular (Hanover, Germany). 
The company provided detailed characterization of the NPs. 
To test whether the NPs were contaminated with bacteria, 
a limulus amebocyte lysate endotoxin assay was conducted 
by Clongen Labs (Germantown, MD, USA).
cell culture and PtNP treatment
Proliferating normal human epidermal keratinocytes 
(NHEKs) from adult donors derived from three individu-
als (Lonza, Basel, Switzerland) were cultured in 75 cm2 
cell-culture flasks at 37°C in 5% CO
2
 atmosphere in kera-
tinocyte growth medium (keratinocyte cell basal medium 
supplemented with KGM-Gold™ SingleQuots™ [Lonza]): 
bovine pituitary extract, human endothelial growth factor, 
insulin (bovine), hydrocortisone, gentamicin–amphotericin B 
(GA-1000), epinephrine, and transferrin.
In several articles, the matter of units used for the NP 
dose used (mass/number/concentration) has been raised.12,13 
We decided to use µg/mL concentrations, as this unit of 
measurement has been proposed as most appropriate for 
in vitro toxicity testing of NPs.14 Different concentrations 
of PtNPs (6.25, 12.5, and 25 µg/mL) were added to the 
cultured cells 1 day after their seeding on multiwell plates, 
and these cells were incubated for appropriate time periods 
(24 and 48 hours).
Transmission electron microscopy
Keratinocytes cultured in multiwell plates were fixed in 5% 
and 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.3, 
at 10°C (Polysciences, Warrington, PA, USA) for 24 hours 
in each concentration. Next, they were washed several 
times in the buffer, removed from the wells, and transferred 
to Eppendorf tubes. They were postfixed in 1.5% osmium 
tetroxide in cacodylate buffer for 1 hour. After fixation, cells 
were washed in cacodylate buffer again and dehydrated in 
50%, 70%, 96%, and 100% ethanol. Finally, they were treated 
with propylene oxide twice for 5 minutes and embedded in a 
Poly/Bed 812 (Polysciences). After polymerization, 70 nm-
thick sections were cut on a Reichert (Depew, NY, USA) 
Ultracut ultramicrotome, collected on copper Formvar-coated 
single-slot grids, and contrasted with uranyl acetate and lead 
citrate. Sections were viewed and photographed using a JEOL 
(Tokyo, Japan) 100 SX TEM.
Viability and cytotoxicity tests
To measure cell viability and cytotoxicity, MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 
and adenosine triphosphate (ATP) assays were carried out. 
For the MTT test, NHEKs were seeded on 96-well plates 
(4 × 103 cells/well). Following 24- and 48-hour stimula-
tion with PtNPs (6.25, 12.5, and 25 µg/mL), thiazolyl blue 
tetrazolium bromide (Sigma-Aldrich, St Louis, MO, USA) 
was added for an additional 3.5 hours to a final concentra-
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Platinum nanoparticles and keratinocytes
described before.15 Absorbance was measured in an Infinite 
M200 microplate reader (Tecan, Männedorf, Switzerland) at 
570 nm with a reference wavelength of 650 nm. Absorbance 
of PtNPs in cell-culture medium measured in the absence of 
cells (NP background) was subsequently subtracted from the 
total absorbance of the NP-treated cells. Four independent 
experiments were done, each performed in triplicate. The 
mean absorbance value for each PtNP concentration was 
divided by the mean value for control cells and thus presented 
as a percentage of control (control treated as 100%).
Cell viability was analyzed by quantification of intracel-
lular ATP content, as described before.16 Cells seeded on 
96-well plates (4 × 103 cells/well) were treated for 24 and 
48 hours with PtNPs. The ATPlite™ luminescence assay 
system (PerkinElmer, Waltham, MA, USA) was used for 
ATP determination. Luminescence was measured using the 
Infinite M200 microplate reader. The mean luminescence 
value for each PtNP concentration was divided by the mean 
value for control cells, and presented as percentage of control 
(control treated as 100%).
caspase 3/7 and 9 activity
The activity of caspases 3 and 7 was measured using 
Caspase-Glo 3/7 Assay (Promega, Fitchburg, WI, USA), as 
described before.15 NHEKs (8 × 103 per well) were seeded 
on twelve-well plates and exposed to 12.5 and 25 ug/mL 
PtNPs for 24 and 48 hours. Protein extracts (3 µg) were 
mixed with 40 µL of Caspase-Glo® 3/7 Reagent on white 
96-well plates. After 120 minutes of incubation, lumines-
cence was measured with the Infinite M200 microplate 
reader. The experiment was repeated three times, and each 
was performed in duplicate. Mean luminescence value for 
each PtNP concentration was divided by the mean value 
for control cells and thus presented as percentage of control 
(control treated as 100%).
For determination of caspase 9 activity, NHEKs were 
seeded on twelve-well plates at a density of 8 × 103 cells 
per well and stimulated the next day with 12.5 or 25 µg/mL 
of PtNPs for 24 or 48 hours. Unstimulated cells served as 
a control. Cells were lysed in 50 µL of radioimmunopre-
cipitation assay buffer containing protease and phosphatase 
inhibitors (10 µM; Roche, Basel, Switzerland). Supernatants 
were collected by spinning of samples at 14,000 rpm for 
15 minutes at 4°C. Three micrograms of isolated protein 
was mixed with 30 µL of Caspase-Glo 9 substrate on a white 
96-well plate. The plate was incubated in the darkness for 
2 hours, and luminescence was measured with the Infinite 
M200 microplate reader. Three independent experiments 
were carried out, each performed in duplicate. The mean 
luminescence value for each PtNP concentration was divided 
by the mean value for control cells and thus presented as a 
percentage of control (control treated as 100%).
comet assay
The level of DNA damage was tested by electrophoresis of 
single cells in agarose gel, with the experiment being carried 
out exactly as described before,16 and two concentrations of 
PtNPs (12.5 and 25 µg/mL) were used at two time points 
(24 or 48 hours). The data were collected for 50 randomly 
selected comets from each slide. Three independent experi-
ments were done, with two replicates each (number of cells 
per condition = 300).
cell migration
NHEKs were seeded on six-well plates (4 × 104 per well). 
At 24 and 48 hours after PtNP addition, cell migration was 
recorded for 90 minutes with 1.5-minute time lapse using the 
Leica DMI6000 B microscope (Leica Microsystems, Wetzlar, 
Germany) equipped with Leica Application Suite Advanced 
Fluorescence software. The tracks of individual cells were 
determined from series of changes in the cell-centroid posi-
tions, pooled and analyzed to determine the velocity of cell 
movement. All analyses were done using Hiro software 
 version 1.0.0.4.16 The experiment was performed three times, 
and the data were collected each time from 50 cells. Final 
data are presented as mean values for 150 cells.
Western blot
Activation of mitogen-activated protein kinases (MAPKs) 
and protein kinase B (Akt) was investigated by Western 
blot using procedures previously described.16 The follow-
ing antibodies and dilutions were used: Akt (1:1,000; Cell 
Signaling Technology, Danvers, MA, USA), Phospho-Akt 
(1:2,000; Cell Signaling Technology), stress-activated pro-
tein kinase (SAPK)/c-Jun N-terminal kinase (JNK) (1:500; 
Cell Signaling Technology), Phospho-SAPK/JNK (1:500; 
Cell Signaling Technology), p38 MAPK (1:1,000; Cell 
Signaling Technology), Phospho-p38 MAPK (1:500; 
Cell Signaling Technology), phosphorylated extracellular 
signal-regulated kinase (p-ERK)-1/2 MAPK (1:2,000; Cell 
Signaling Technology), Phospho-ERK1/2 MAPK (1:1,000; 
Cell Signaling Technology). Tubulin (1:2,000,  Calbiochem; 
Merck Millipore, Billerica, MA, USA) was used as a 
loading control. The following secondary antibodies were 
used: peroxidase-conjugated antirabbit (1:3,000–1:10,000; 
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antimouse (1:20,000, Pharmingen; BD Biosciences, San 
Jose, CA, USA).
colony-reduction assay
The assay was performed as described previously by 
Sieprawska-Lupa et al.17 Briefly, Escherichia coli (33694; 
American Type Culture Collection [ATCC], Manassas, 
VA, USA) and Staphylococcus aureus (ATCC 29213) were 
grown to the midexponential phase in Luria-Bertani broth or 
tryptic soy broth, respectively. Then, bacteria were washed 
four times in phosphate-buffered saline and diluted to a 
final concentration of 2 × 105 colony-forming units/mL in 
Roswell Park Memorial Institute 1640 supplemented with 
10% Hank’s balanced salt solution. PtNPs were diluted in 
water to a designated concentration. Nine parts bacteria 
were incubated with one part PtNPs for 2 hours at 37°C. 
As a control, bacteria were incubated in the same solution, 
but without the PtNPs. Each assay point was repeated at 
least three times. Each sample was diluted 1:100, 1:200, and 
1:400 and plated in triplicate on tryptic soy broth or Luria-
Bertani agar plates. After 24 hours’ incubation at 37°C, 
colonies were counted. Data are shown as the percentage 
of bacteria survival. The control sample was arbitrarily set 
as 100% survival.
Cell-cycle analysis by flow cytometry
The impact of different concentrations of two sizes of PtNPs 
(0, 12.5, and 25 µg/mL) on cell-cycle and DNA accumu-
lation was examined in keratinocytes following 24- and 
48-hour incubation by flow cytometry. Control untreated 
cells (1 × 106) as well as the cells following 12.5 µg/mL 
and 25 µg/mL treatment with PtNPs at two time points were 
fixed in suspension employing fridge-cold 70% ethanol. 
The cells were further washed in phosphate-buffered saline 
without Ca2+ and Mg2+ (Invitrogen; Life Technologies, 
Carlsbad, CA, USA), treated with DNase-free ribonuclease 
(100 µg/mL, Sigma-Aldrich) to remove the RNA fraction, 
and subsequently stained with propidium iodide (50 µg/mL, 
Sigma-Aldrich) to visualize DNA content. Samples were 
evaluated by flow cytometry (LSR II; BD Biosciences).
statistical analysis
All results are the means of at least three independent 
 experiments ± standard deviation. The data were analyzed 
using Student’s t-test, and only in case of comet-assay 
data were calculated by Tukey’s rank-invariant resampling 
test. Statistical significance was accepted at the level of 
P # 0.05.
Results
Ultrastructure of PtNP-treated 
keratinocytes
To verify the interaction between PtNPs and normal human 
keratinocytes, we treated the cells with 5.8 nm and 57 nm 
PtNPs and performed TEM analysis. When compared 
with the control (Figure 1A–C), keratinocytes treated with 
PtNPs in 12.5 µg/mL concentration for 24 hours showed 
cytoplasmic endosomes filled with electron-dense material, 
probably aggregates of PtNPs (Figure 1D and E). When the 
concentration of NPs was increased to 25 µg/mL, there were 
more endosomes/lysosome-like organelles visible in the 
cytoplasm (Figure 1H). Longer exposure of keratinocytes 
to PtNPs increased the number and size of lysosomes in 
the cytoplasm filled with NPs and cell-engulfed material 
(Figure 1G). There were no obvious ultrastructural changes 
noticed in the nucleus except changes in its shape (Figure 1F). 
In some cells, the nucleolus was observed on the nucleus 
territory (Figure 1F and G).
Besides weak changes in the nucleus, no clear changes 
in cell morphology were observed in keratinocytes treated 
for 24 hours with 5.8 nm PtNPs (Figure 1I). While the cells 
treated with 57 nm PtNPs looked generally fine, strong accu-
mulation of NPs was observed when higher doses were used 
(12.5 and 25 µg/mL, Figure 1I). The material accumulated 
around cell nuclei. This suggests that 57 nm PtNPs undergo 
endocytosis, similarly to 5.8 nm PtNPs, but for small NPs 
TEM is necessary for the visualization of NP endocytosis.
effects of PtNPs on cell viability  
and metabolism
To estimate the cytotoxic effects of PtNPs on keratinocytes, 
we carried out a viability assay (MTT) and metabolic activity 
test (ATP content). Cells were treated with PtNPs of two sizes 
(5.8 and 57 nm) in three concentrations: 6.25, 12.5 and 
25 µg/mL. The experiment was conducted at two time points: 
24 and 48 hours. Untreated cells served as a control.
In the MTT assay, we observed that both the size and 
the concentrations of NPs altered their influence on cell 
 viability. However, the observed changes were not statisti-
cally significant (Figure 2A).
In the case of metabolic activity, we noticed dose- and 
time-dependent decrease of ATP content in cells treated 
with PtNPs. Both NP fractions decreased cell metabolism, 
but this effect was stronger for the cells treated with the 
smaller NPs than with the bigger ones, and in most cases 
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Platinum nanoparticles and keratinocytes
 following PtNP administration. Generally, for the highest 
concentration of 5.8 nm PtNPs (25 µg/mL), we observed a 
decrease in cell metabolism by 29% after 24 hours and by 
24% after 48 hours of exposure. For the lowest concentration, 
the changes were 18% and 20% decrease after treatment of 
cells for 24 and 48 hours, respectively (Figure 2B, left panel). 
In case of cells treated with the bigger NPs, ATP content was 
decreased by 16% and 27%, respectively, after administration 
of the highest concentration of NPs (25 µg/mL) for 24 and 
48 hours and 12% after 24 hours for the lowest concentration 
(6.25 µg/mL). There was no statistically significant change 
after 48 hours (Figure 2B, right panel).
Figure 1 (A–I) Ultrastructure of keratinocytes treated with 5.8 nm platinum nanoparticles (PtNPs). (A–C) Keratinocytes from the control fixed after 24 hours (A) and 
48 hours (B and C) of in vitro culturing. (D and E) endosome/lysosome-like organelles in a keratinocyte treated for 24 hours with 12.5 µg/ml PtNPs. electron-dense material 
of an NP aggregate is observed inside an endosome/lysosome. (F and G) Part of a keratinocyte exposed for 48 hours to 12.5 µg/ml and (G) 25 µg/ml PtNPs. (H) endosomes/
lysosomes in a keratinocyte treated with 25 µg/mL PtNPs and fixed after 24 hours. (I) Keratinocytes treated for 24 hours with 5.8 nm PtNPs or 57 nm PtNPs at the indicated 
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Time-lapse monitoring of cell movement was performed to 
estimate the influence of PtNPs on the migratory  potential 
of keratinocytes. As in the other experiments, 5.8 and 
57 nm PtNPs were incubated with keratinocytes for 24 and 
48 hours, and untreated cells served as a control. We did not 
observe any significant inhibition of cell migration for used 
concentrations of PtNPs used in the experiment (Figure 3A 
and B). Thus, the treatment of cells with PtNPs at indicated 
concentrations and time points has no effect on the migratory 
activity of keratinocytes.
cell cycle
The impact of PtNPs on cell-cycle and DNA accumulation in 
keratinocytes was evaluated by employing flow cytometry. 
The data showed no significant difference in content of qui-




 phase) or proliferating cells represented 
in both S and G
2
/M phases. Moreover, we did not observe any 
considerable accumulation of polyploidy following treatment 
with PtNPs of two sizes (Figure 4A). The effect was similar 
for cells treated with the agent for 24 and 48 hours. Similarly, 
the ratio between quiescent and proliferating cells (computed 




 phase to the sum of cells in both 
the S and G
2
/M phases) confirmed that there was no major 
impact of PtNPs on cell proliferation and accumulation of 
cells with an abnormal, polyploid number of chromosomes 
(Figure 4B).
comet assay
To measure DNA damage in individual cells, single-cell gel 
electrophoresis (comet assay) was carried out. Genotoxic 
effects triggered by 5.8 nm PtNPs were time- and dose-
dependent. Smaller NPs caused significant changes in the 
level of damaged DNA, as observed after 48 hours of treat-
ment at a concentration of 12.5 µg/mL. The use of a higher 
concentration resulted in the augmentation of the DNA comet 
formation, reaching a level of 13.2% and 18.2% after 24 and 
48 hours, respectively (Figure 5A). In the experiment where 
the bigger NPs were used, the amount of DNA in a comet tail 
was slightly higher, but statistically significant in compari-
son to control only for the concentration 25 µg/mL and after 
24 hours of incubation. Other time points and lower concentra-
tions were not statistically significant, and the effects were not 
as visible as in the case of smaller NPs (Figure 5B).
activation of apoptosis
As an indicator of apoptosis-related processes, caspase 3/7 and 





















































































































** ** ** ** ** ** ** ** ***
*
Figure 2 (A and B) Biological activity of cells treated with platinum nanoparticles (PtNPs). (A) an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay 
was carried out to measure cell viability. Normal human epidermal keratinocytes (NheKs; plated at a density of 4 × 103 per well of 96-well plates) were treated with PtNPs 
of two sizes (5.8 and 57 nm) in concentrations of 6.25, 12.5, and 25 µg/ml at indicated time points. Untreated cells served as a control. For statistics, student’s t-test was 
performed. The graphs (left panel and right panel) represent the mean ± standard deviation (SD) of five independent experiments, each performed in quintuplicate (number 
of wells = 25). (B) an adenosine triphosphate assay was performed to determine metabolic activity of cells. NheKs (plated as in (A)) were treated with PtNPs as described 
in (A). Untreated cells served as a control. For statistics, student’s t-test was performed (*P , 0.05; **P , 0.01; ***P , 0.001). The graphs represent the mean ± sD of three 
independent experiments, each performed in triplicate (number of wells = 9).
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Platinum nanoparticles and keratinocytes
9 after treatment of keratinocytes for 24 hours. In case of 
smaller NPs, caspase activity increased about 24% for the 
concentration 12.5 µg/mL and 35% for 25 µg/mL. The use 
of 57 nm NPs resulted in 8% and 10% activation of caspase 9 
for lower and higher concentrations, respectively, in compari-
son to control cells. However, after 48 hours of keratinocyte 
incubation with NPs, the activity of caspase 9 was below the 
control value for both types of PtNPs (Figure 5C, upper panel). 
Distinct results were obtained for caspase 3/7. Both small as 
well bigger NPs caused a decrease in activity of these cas-
pases in comparison to basic activity present in control cells 
(Figure 5C, lower panel). The decline in caspase 3/7 activity 
was insignificantly stronger in comparison to control cells 
after 24 hours than after 48 hours in the case of cells incubated 
with smaller NPs (Figure 5C, lower left panel). In the case 
of bigger NPs, we observed another tendency: caspase 3/7 
activity was slightly below the basic level after 24 hours, and 
then a more significant decline was observed after 48 hours 
of treatment (Figure 5C, lower right panel).
activation of signaling pathways  
by PtNPs
MAPKs (p38, JNK and ERK1/2) and Akt are involved in 
relaying extracellular stimulations to intracellular responses. 
The MAPKs coordinately regulate cell proliferation, differ-
entiation, motility, and survival. Akt is a key regulator of cell 
metabolism, but plays also a crucial role in the regulation 
of such cellular processes as growth, metabolism, survival, 
and proliferation. These kinases are quickly activated upon 
stress conditions to trigger signals towards appropriate tran-
scription factors.
Treating keratinocytes with PtNPs, we observed enhanced 
phosphorylation of ERK1/2, JNK, and Akt, but not p38 
(Figure 6A–D). The activation of these kinases was observed 
at two time points of the experiment (0.5 and 4 hours), and 
then after 24 hours the phosphorylation was as in the control 
or even below the signal for control cells (in the case of Akt 
















































































Figure 3 (A and B) cell migration. Normal human epidermal keratinocytes seeded on six-well plates (4 × 104 per well) were exposed to 5.8 (A) and 57 (B) nm platinum 
nanoparticles (PtNPs) in concentrations of 12.5 and 25 µg/ml for 24 hours and 48 hours. cell migration was recorded for 90 minutes with 1.5-minute time lapse using a leica 
DMI6000B microscope equipped with leica application suite advanced Fluorescence software. The tracks of individual cells were determined from the series of changes in 
the cell centroid positions, pooled, and analyzed to determine the total length of the cell trajectory (left panels). all analyses were performed using hiro software version 
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The antimicrobial activity of silver NPs is well known. 
 However the properties of PtNPs in this field have not been 
fully investigated.18 Therefore, we determined the antimi-
crobial properties of PtNPs against Gram-negative (E. coli) 
and Gram-positive (S. aureus) bacteria. Both pathogens were 
treated with two concentrations (2 and 20 µg/mL) of PtNPs 
of two sizes (5.8 nm and 57 nm). Viability inhibition was 
significant in a concentration-dependent manner only in the 
case of treatment of E. coli with the smallest NPs. Notably, 
significant growth inhibition was observed already at the 
2 µg/mL concentration of PtNPs, with bacterial growth esti-
mated at about 66.5% ± 10.1% of control cells, the viability 
of which was set as 100% (Figure 7A). The data obtained for 
S. aureus were not significant. In the case of bigger PtNPs, 























































Figure 4 (A and B) Cell-cycle phases and DNA content in keratinocytes by flow cytometry following treatment with platinum nanoparticles (PtNPs). (A) Percentage content 
of cells in each cell-cycle phase (g0/g1, s, g2/M) as well as polyploid cells (.4 n) following 24- and 48-hour treatment with different doses of 5.8 and 57 nm PtNPs. The bars 
represent average data (means ± standard deviation [sD]). (B) representative histograms showing DNa content of cells following treatment with PtNPs and stained with 
propidium iodide. The numbers represent the ratio of nondividing, quiescent, and proliferating cells (Q/P) in each sample, calculated as ratio between cells in g0/g1 phase to 
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Platinum nanoparticles and keratinocytes
highest concentration used in our study (20 µg/mL), and 
was estimated at about 70% of the control cells (Figure 7B). 
Bigger NPs did not display antimicrobial properties towards 
S. aureus. Obtained data demonstrated the differential anti-
microbial potential of PtNPs.
Discussion
NPs have become more and more commonly used in scientific 
studies and in industry. Although NPs have comprehensive 
applications, their potential effects on organisms and 
environment are not well clarified yet; in particular, their 
long-term effects have not been estimated. There is a growing 
list of reports indicating that NPs might be medically and 
environmentally toxic, as their high surface-to-volume 
ratio makes the particles of some metals very reactive or 
catalytic.19 There is also evidence that NPs pass through cell 
membranes and interact with cellular structures, and thus 
have a direct impact on cell functioning and consequently 
on cell viability.
PtNPs might have potential application as scavengers 
of ROS in different types of cells. ROS are important 
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oxidative stress when they appear in high concentrations. 
Such activity may eventually lead to cell damage, caused 
by DNA damage, lipid peroxidation, and oxidations of 
amino acids.21 It has been shown that PtNPs influence many 
processes by modulating the level of ROS production. Kim 
and coworkers7 showed that PtNPs inhibit formation of 
osteoclasts by impairing the receptor activator of nuclear 
factor-κB ligand (RANKL) signaling. Thus, PtNPs could 
protect against bone loss by modulation of oxidative stress. 
Similar data were delivered by Nomura et al,8 showing 
that PtNPs inhibit RANKL-stimulated osteoclast differ-
entiation via their ROS-scavenging property. Moreover, a 
study by Clark et al22 showed that PtNPs reduce oxidant-
mediated apoptosis in target cells, judging by the activation 
of caspase 3.  Nevertheless, there are also reports suggesting 
that PtNPs might have toxic effects on cells. They cause, for 
example, DNA-strand breaks in human colon carcinoma 
cells (HT29) in a concentration-, time- and size-dependent 
manner. However, such DNA damage was not accompanied 
by the formation of ROS.23,24
In this study, we used PtNPs coated with PVP, which 
represent a polymer increasingly widespread in medicine 
and foodstuffs. First of all, PVP is used as a binder in many 
pharmaceutical tablets. Also, PVP is used as a stabilizer 
of different kinds of food (E1201) and also in the wine 
industry as a fining agent for white wine. This chemical 
is approved for many uses (inactive ingredients in FDA-
approved drugs).
In human primary keratinocytes treated with 5.8 nm 
PtNPs, we observed at the TEM level that PtNPs cause cell 
membrane folding around the NPs, producing a sac-like bub-
ble into which the material is incorporated and NPs are local-
ized within intracellular vacuoles. The localization of PtNPs 
in intracellular vacuoles suggests endosomal containment 
and an uptake mechanism involving endocytosis. Such a 
mechanism has already been described for silver NPs.25,26 
Cells treated with NPs displayed changed morphology after 
24 and 48 hours of incubation in comparison to control 
cells, but only when analyzed by TEM. No morphological 
changes could be observed for 5.8 nm PtNPs treated for 
24 hours, when bright-field microscopy was applied. For the 
cells treated with larger NPs (57 nm), the accumulation of 
material was observed using bright-field microscopy already 
after 24 hours of exposition. Nevertheless, the data from cell-
viability assays and migratory tests were not significantly 





































































































































Figure 5 (A–C) Determination of DNa quality and activation of caspases in platinum nanoparticle (PtNP)-treated normal human epidermal keratinocytes (NheKs). 
(A and B) DNa damage in NheKs was investigated by comet assay. cells were plated at a density of 2.1 × 103 cells/cm2. after 24 hours, NheKs were treated with 12.5 and 
25 µg/ml for 24 and 48 hours. Mean values of the percentage of DNa in the comet tail are presented. Images were made using the computer program comet Plus (left 
panels). statistical analyses were calculated using Tukey’s rank-invariant resampling test (*P , 0.05; **P , 0.01; ***P , 0.001). The data represent the means ± standard 
deviation (sD) from DNa damage in 100 cells, measured in three independent experiments (right panels). (C) activation of caspases. The apoptotic effect triggered by 
PtNPs was measured by the determination of caspase 9 and 3/7 activity. a luminescent assay was performed using 3 µg protein isolated from NheKs after incubation with 
12.5 and 25 µg/ml PtNPs for 24 and 48 hours. The graph represents the means ± sD of three independent experiments. student’s t-test was carried out for statistics 
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Platinum nanoparticles and keratinocytes
We observed a difference in toxicity level between 
smaller and bigger PtNPs. Smaller NPs triggered a stron-
ger decrease in the metabolic activity of treated cells and 
stronger DNA damage, as well as higher activity of signal-
ing pathways. Similarly to what was observed in the case of 
silver NPs, the size of PtNPs was an important factor in the 
induction of genotoxic and cytotoxic effects.7,27,28 Western 
blot data showing activation of signaling pathways impor-
tant for cell survival and proliferation indicate that PtNPs 
trigger stressful conditions for keratinocytes during the first 
few hours of treatment, resulting in enhanced phosphory-
lation of ERK1/2, JNK, and Akt. However, the activity of 
these kinases returns to the level observed in control cells 
after 24 hours, and thus PtNP-related stress does not affect 
homeostasis in a stable way. Interestingly, the decrease in cell 
metabolism was accompanied by a slight decrease in activa-
tion of caspase 9 after 24-hour treatment of cells with NPs, 
and then after 48 hours a decline of activity was observed. 
In the case of caspase 3/7, a significant decline of activity 
was seen at both time points of experiment. Such a phenom-
enon, that caspase activity is reduced under toxin treatment, 
was observed by Tao and coworkers when cells were treated 
with anticancer drugs (doxorubicin, dactinomycin).29 These 
authors suggested that this might be due to the effects of 
caspase leakage, ATP depletion, or cell death.29
We showed here that PtNPs display antimicrobial proper-
ties against E. coli and S. aureus, pathogens that can cause 
serious local and systemic life-threatening infections. We 
demonstrated that the susceptibility of E. coli to PtNPs is 
significantly higher in comparison to S. aureus. Our results 
corroborate the data obtained using silver NPs, since the mini-
mal inhibitory concentration of silver NPs against E. coli was 
estimated to be ten times lower in comparison to S. aureus.30 
Such an effect is probably a consequence of the thick pep-
tidoglycan layer of the S. aureus cell wall, preventing the 





































































Figure 6 (A–D) activation of erK, akt, p38, and JNK by Western blot analysis. Normal human epidermal keratinocyte cells were cultured in 60 mm tissue-culture dishes at 
a density of 9.5 × 103 cells/cm2. The cells were exposed to 12.5 and 25 µg/ml PtNPs for 0.5, 4, and 24 hours. Untreated cells, harvested together at the 0.5-hour time point, 
served as a control. at the time of NP addition, the whole medium was exchanged in both treated and untreated cells. Tubulin was used as an internal control to monitor 
for equal loading. The data are representative of three independent experiments. 
Abbreviations: PtNPs, platinum nanoparticles; p-erK, phosphorylated extracellular signal-regulated kinase; p-akt, phosphorylated protein kinase B; p-JNK, phosphorylated 
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era of multiresistant strain appearance, the discovery of new, 
nonantibiotic compounds with antimicrobial potential is a 
promising tool in the treatment of infectious diseases.
We have recently shown that silver NPs possess quite 
strong genotoxic and cytotoxic effects on human primary 
keratinocytes.16 However, they are among the most com-
mercialized NPs due to their antimicrobial potential. 
We are surrounded by therapeutic agents, household 
products, textiles, and cosmetics containing silver NPs. 
Data presented in this study show that an important 
advantage of PtNP use may be related to their antibac-
terial properties and lack of significant toxic effects on 
keratinocyte biology and function, as was shown in the 
case of silver NPs.16 However, it has to be mentioned that 
effects observed in vitro may differ from the effects trig-
gered by NPs on human skin. The skin acts as a barrier 
to potentially dangerous materials, and it is not clear yet 
whether NPs penetrate the skin’s surface. Further in vivo 
studies are essential to clarify this issue. In contrast to 
previous studies, recently obtained data with the use of 
confocal microscopy allowed Campbell et al to show that 
fluorescent polystyrene NPs applied in aqueous suspension 
could infiltrate only the stratum disjunctum, ie, skin layers 
in the final stages of desquamation.32 Thus, it is possible 
that the use of NPs on the skin directly does not trigger 
such toxic effects as observed in vitro. Nevertheless, one 
could consider whether instead of more toxic silver NPs, 
PtNPs could be used in various body products.
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Figure 7 (A and B) antibacterial activity of platinum nanoparticles (Pt-NPs). concentration-dependent antibacterial effect of Pt-NPs on Escherichia coli (A) and Staphylococcus 
aureus (B). antimicrobial activity was determined using a colony-reduction assay. Bacteria were incubated alone or with PtNPs at concentrations of 2–200 µg/ml for 2 hours 
at 37°c, then plated onto agar plates to determine the numbers of colony-forming units. Percentage survival was calculated and compared to bacteria grown without PtNPs 
(100% survival). Mean values ± standard error of mean of three independent experiments performed in triplicate are shown. 
Notes: *P , 0.05; ***P , 0.001.
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